Privia Health Group (NASDAQ:PRVA - Free Report) had its price objective boosted by Barclays from $19.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. Barclays currently has an equal weight rating on the stock.
Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $28.00 price objective on shares of Privia Health Group in a research note on Wednesday, August 14th. Truist Financial boosted their price target on shares of Privia Health Group from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Friday. Robert W. Baird lifted their target price on Privia Health Group from $23.00 to $24.00 and gave the company an "outperform" rating in a report on Monday, August 26th. Finally, KeyCorp initiated coverage on Privia Health Group in a report on Friday, October 11th. They set an "overweight" rating and a $23.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Privia Health Group currently has a consensus rating of "Buy" and an average target price of $25.07.
View Our Latest Research Report on Privia Health Group
Privia Health Group Stock Performance
Shares of NASDAQ:PRVA traded down $1.23 during mid-day trading on Friday, reaching $21.30. 1,626,114 shares of the company's stock were exchanged, compared to its average volume of 870,336. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of 180.35, a PEG ratio of 4.80 and a beta of 0.76. Privia Health Group has a twelve month low of $15.92 and a twelve month high of $24.35. The business's fifty day moving average price is $18.41 and its 200-day moving average price is $18.34.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.02). The company had revenue of $422.30 million during the quarter, compared to the consensus estimate of $411.50 million. Privia Health Group had a net margin of 0.88% and a return on equity of 2.42%. The business's revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 EPS. Analysts predict that Privia Health Group will post 0.17 EPS for the current fiscal year.
Insider Buying and Selling at Privia Health Group
In other Privia Health Group news, CEO Parth Mehrotra sold 135,142 shares of Privia Health Group stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $18.50, for a total transaction of $2,500,127.00. Following the sale, the chief executive officer now directly owns 247,771 shares of the company's stock, valued at approximately $4,583,763.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.20% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV raised its position in Privia Health Group by 34.6% in the third quarter. KBC Group NV now owns 3,385 shares of the company's stock worth $62,000 after acquiring an additional 871 shares during the period. MQS Management LLC bought a new position in Privia Health Group in the 3rd quarter worth $217,000. Victory Capital Management Inc. raised its holdings in Privia Health Group by 402.9% during the third quarter. Victory Capital Management Inc. now owns 179,049 shares of the company's stock valued at $3,260,000 after acquiring an additional 143,446 shares during the period. GSA Capital Partners LLP lifted its position in shares of Privia Health Group by 228.1% in the third quarter. GSA Capital Partners LLP now owns 50,975 shares of the company's stock valued at $928,000 after acquiring an additional 35,439 shares in the last quarter. Finally, Olympiad Research LP bought a new position in shares of Privia Health Group in the third quarter worth about $195,000. 94.48% of the stock is owned by institutional investors.
About Privia Health Group
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Read More
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
